default author photo

Silvia Lamonica

affiliation not provided to SSRN

SCHOLARLY PAPERS

1

DOWNLOADS

64

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Sarilumab Plus Standard of Care Versus Standard of Care for the Treatment of Severe COVID-19: A Phase 3, Randomized, Open-Labeled, Multi-Center Study (ESCAPE Study)

Number of pages: 38 Posted: 05 Dec 2022
Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Fondazione Policlinico Universitario A. Gemelli IRCCS - Section of Infectious Diseases, ASST Santi Paolo e Carlo, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Fondazione Policlinico Universitario A. Gemelli IRCCS, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Fondazione Policlinico Universitario A. Gemelli IRCCS - Section of Infectious Diseases, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, ASST Santi Paolo e Carlo, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, University of Rome Tor Vergata - Department of Systems Medicine, affiliation not provided to SSRN, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Sapienza University of Rome, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, University of Rome Tor Vergata - Faculty of Medicine and Surgery, University of Rome Tor Vergata - Department of Systems Medicine, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, University of Milan - Clinic of Infectious Diseases and Tropical Medicine, Lazzaro Spallanzani National Institute for Infectious Diseases, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Clinical Department and Independent
Downloads 64 (924,743)

Abstract:

Loading...

Interleukin-6 receptor inhibitors, Sarilumab, SARS-CoV-2 infection, Severe COVID-19 pneumonia, randomized clinical trial